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Abstract: 
Preliminary investigation of the radioiodinated (S,S)-reboxetine analogue, 123I-INER, in baboons 
showed this tracer to have promise for imaging the noradrenaline transporter (NAT) using single photon 
emission computed tomography (SPECT). More recently the radioiodinated (R,S)-stereoisomer of 123I-
INER , 123I-NKJ64  has been synthesised and preliminary evaluation in rats has been reported.  This paper 
reports the brain distribution and pharmacokinetic properties of 123I-NKJ64 in baboons and compares 
results with 123I-INER data in the same species. SPECT studies were conducted in two ovariectomised 
adult female baboons using two different protocols: (1) bolus of 123I-INER or 123I-NKJ64; and (2) bolus 
plus constant infusion of 123I-NKJ64 with reboxetine (2.0 mg/kg) administration at equilibrium. 
Following bolus injection, both radiotracers rapidly and avidly entered the baboon brain. The regional 
brain accumulation of 123I-NKJ64 did not match the known distribution of NAT in baboon brain, 
contrasting with previous results obtained in rats. Conversely, the regional distribution of 123I-INER was 
consistent with known distribution of NAT in baboon brain. No displacement of 123I-NKJ64 was observed 
following administration of reboxetine. This contrasts with previous data obtained for 123I-INER, where 
60% of specific binding was displaced by a lower dose of reboxetine. These data suggest that 123I-NKJ64 
may lack affinity and selectivity for NAT in baboon brain and 123I-INER is the most promising iodinated 
reboxetine analogue developed to date for in vivo imaging of NAT in brain using SPECT. This study 
highlights the importance of species differences during radiotracer development and the stereochemical 
configuration of analogues of reboxetine in vivo. 
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Introduction: 
 Dysregulation of the noradrenergic system has been implicated in multiple psychiatric and 
neurodegenerative disorders, including: depression, post-traumatic stress, anxiety, attention-
deficit/hyperactivity disorder, Alzheimer’s disease and Parkinson’s disease (Grandoso et al., 2004; 
Kiyono et al., 2004; Kung et al., 2004; Lakshmi et al., 2008; McConathy et al., 2004; Zeng et al., 2009). 
Non-invasive imaging using a selective noradrenaline transporter (NAT) radiotracer and either positron 
emission tomography (PET) or single photon emission computed tomography (SPECT) could be used for 
in vivo investigations of disease progression and treatment response. In addition a NAT radiotracer would 
enable studies investigating novel drugs targeted at the NAT, such as drug occupancy studies, thereby 
aiding the drug discovery process. A radiotracer specific for the in vivo assessment of changes in NAT 
density, is therefore desirable. 
Multiple NAT-selective radiotracers have been developed over the years for in vivo and in vitro 
brain imaging, including: 11C-desipramine (11C-DMI) and its hydroxylated derivate (R)-11C-OHDMI; 11C-
nisoxetine and its derivatives (125I-INXT and 125I-PYINXT); 11C-thionisoxetine; 11C-oxaprotiline; 11C-
lortalamine; 11C-talopran; 11C-talsupran; two 11C-labelled analogues of mazindol; and 11C-labelled, 18F-
labelled and 123I-labelled analogues of reboxetine (McConathy et al., 2004; Schou et al., 2007; Schou et 
al., 2006; Zeng et al., 2009). The most promising PET radiotracers developed for in vivo imaging of the 
NAT are analogues of reboxetine and include: (S,S)-11C-MeNER, (S,S)-18F-FMeNER-D2 and (S,S)-18F-
FRB-D4 (Schou et al., 2007; Schou et al., 2006). For in vivo imaging of the NAT using SPECT, the most 
promising radiotracers developed to date are also reboxetine analogues, namely 123I-INER (also denoted 
(S,S)-IPBM) (Kanegawa et al., 2006; Tamagnan et al., 2007) and 123I-NKJ64 (Tavares et al., 2011a) (Fig. 
1).  
123I-INER has a high affinity for the NAT in rat forebrain, with a KD value of 1.30 ± 0.46 nM. In 
rat biodistribution studies, 123I-INER displayed good initial brain uptake with maximum accumulation in 
the rat brain at 30 minutes post-injection (0.54% injected dose/g). The washout in rat brain was gradual 
and a high midbrain-to-striatum ratio was observed at 180 minutes post-injection (Kanegawa et al., 2006). 
In baboons, a slow washout from the brain, over more than 2 hours, was observed. Despite the longer 
physical half-life of 123I being compatible with slower kinetics, the washout of 123I-INER over 2 hours in 
vivo in baboons suggested improvement of NAT radiotracers for SPECT was desirable  (Tamagnan et al., 
2007). Thus, in order to develop a novel radiotracer for imaging of NAT in brain using SPECT with 
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improved kinetics, we investigated novel iodinated analogues of reboxetine (Jobson et al., 2008a; Jobson 
et al., 2009; Jobson et al., 2008b). Our lead candidate, NKJ64, a stereoisomer of INER was found to have 
high affinity for the NAT in rat brain (Ki of 8.4 ± 1.7 nM) (Jobson et al., 2009). Recently, we reported the 
radiosynthesis of 123I-NKJ64 (Tavares et al., 2011b) and the evaluation of 123I-NKJ64 in rat brain tissue 
revealed a nanomolar affinity for NAT (KD of 4.82 ± 0.87 nM in cortical homogenates) (Tavares et al., 
2011a). Additional evaluation of 123I-NKJ64 in rats showed: 1) the regional distribution of 123I-NKJ64 
binding to be consistent with the known density of NAT in rodent brain; 2) a maximum uptake of 2.9% of 
the injected dose in brain; 3) a specific to non-specific ratio (locus coeruleus:caudate putamen) of 2.8 at 
30 minutes post intravenous injection; 4) a relatively fast washout from whole brain with an effective 
half-life of  49 minutes (Tavares et al., 2011a). These data from rats indicated that further evaluation of 
123I-NKJ64 in non-human primates was warranted to determine its utility as a SPECT radiotracer for 
imaging of NAT in brain. In this paper the biodistribution and pharmacokinetic properties of 123I-NKJ64 
in non-human primate brain is reported. In addition, a comparative analysis between 123I-NKJ64 and 123I-
INER data in non-human primate brain is presented. 
 
Materials and Methods: 
 
Animals 
All procedures were conducted at Yale University, USA in accordance with institutional animal 
care protocols and in compliance with Federal regulations. Two ovariectomised adult female baboons 
(Papio anubis, 14.9 and 13.7 kg) were used for in vivo studies. One baboon was used to evaluate 123I-
NKJ64 distribution and pharmacokinetic properties and the other baboon was used for studies using 123I-
INER. Baboons were fasted for 24 hours prior to imaging studies. On the SPECT imaging day, 
anaesthesia was induced by intramuscular injection of ketamine (10 mg/kg) and glycopyrrolate (0.1-0.2 
mg/kg). The animal was then transferred to the SPECT camera and immediately intubated with an 
endotracheal tube and anaesthesia was maintained by administering 2.5% isoflurane through a re-
breathing circuit. A period of at least 2 hours between induction of anaesthesia and radiotracer injection 
was allowed, in order to stabilise the baboons under anaesthesia and minimise the effects of the initial 
administration of ketamine on radiotracer uptake, distribution and kinetics. An intravenous perfusion line 
was established in a femoral vein for injection of fluids for hydration and collection of blood samples for 
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metabolite analysis. In the contralateral leg, an additional venous line was used for injection of the 
radiotracer. Body temperature was maintained using a heated water blanket and monitored by rectal 
thermometer. Vital signs, including heart rate, respiration rate, blood pressure and body temperature, were 
monitored every 15 minutes. 
 
General SPECT acquisition protocol 
SPECT studies were performed using a Neurofocus SPECT camera (Neurophysics Inc., USA), 
with a ring of 12 wide-aperture pinhole collimator detectors. Data acquisition started immediately after 
radiotracer injection using consecutive dynamic SPECT scans, in which detectors moved side-to-side and 
in and out to completely sample each slice (Seibyl et al., 2002; Stoddart and Stoddart, 1992). The duration 
of each scan was approximately 20 minutes and a total of up to 18 slices were acquired. An energy 
window of 10% centred at 159 keV, 128×128×64 matrix, zoom of 1 and slice thickness of 5.0 mm were 
used for acquisitions starting at 0 minutes post injection. Acquisition duration was 240 minutes for bolus 
baseline experiments and 420 minutes for bolus plus constant infusion studies with displacement drug. 
Raw SPECT data were reconstructed using Neurofocus proprietary software (Neurofocus Inc., USA) and 
the manufacturer’s recommended iterative reconstruction algorithm, which was based on maximum a-
posteriori (MAP) reconstruction methods, similar to algorithms used for scanning microscopes (Seibyl et 
al., 2002). Injected radioactivity for bolus studies was 222.0 MBq and 432.9 MBq for 123I-NKJ64 and 
123I-INER experiments, respectively; and for bolus plus constant infusion using 123I-NKJ64 the injected 
radioactivity was 264.18 MBq. Venous blood was collected from a femoral vein at selected time points. 
The displacement study was conducted using a bolus plus constant infusion protocol. The bolus/infusion 
(B/I) ratio (or Kbol) was calculated to be 2.5 hours for 123I-NKJ64 using PMOD 3.203 software (PMOD 
Technologies, Switzerland) and results from bolus baseline studies. A Gemini PC 1 (IMED Inc., USA) 
infusion pump with 60 mL syringes was used for infusion of radiotracer. Upon equilibrium, which was 
estimated to occur between 2.5 and 3 hours based on estimations using PMOD 3.203 software, a single 
bolus of 2.0 mg/kg of reboxetine was injected intravenously. 
 
Plasma pharmacokinetic analysis 
For studies using the radiotracer bolus paradigm, venous blood samples (4-5 mL) were obtained 
from the femoral vein prior to start of the study (- 5 minutes) and at 1, 3, 5, 10, 15, 30, 60, 120, 180 and 
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240 minutes post radiotracer injection. For displacement studies, where a bolus plus constant infusion 
paradigm was used, venous blood samples were collected at 15, 30 and 45 minutes prior to reboxetine 
injection and 15, 30, 45, 60 and 120 minutes following reboxetine administration. The samples were 
collected into ethylenediaminetetraacetic acid-coated tubes. Processing and analysis of blood was 
performed using previously established methodology (Baldwin et al., 1995; Baldwin et al., 1993; 
Gandelman et al., 1994; Zoghbi et al., 1992).  
 
Image processing and co-registration with magnetic resonance (MR) imaging  
Reconstructed scans were imported into PMOD 3.203 software and merged into a single file for 
image processing which was performed using PMOD tools, starting with decay correction. Motion 
correction was performed by creating an average image of consecutive scans with absence of motion, 
which was then used as a reference for rigid matching co-registration to all scans in the current study. 
Attenuation correction was performed by applying the Chang algorithm (attenuation coefficient = 0.011 
mm-1) to a semi-automatically drawn volume of interest (VOI) (Chang, 1978).  
T1-weighted MR images were acquired with a GE Signa unit (General Electric, USA) at 1.5 T. 
The T1 sequence was a spoiled gradient recall protocol with the following settings: TR= 25 ms, TE=5 ms, 
NEX=2, matrix=256×256, field of view = 16 cm. T1-weighted MR images were reduced from an initial 
matrix of 256×256 with 112 axial slices (axial slice thickness = 0.7 mm) to a 128×128 matrix, with 20 
axial slices (axial slice thickness = 2.8 mm). Each animal used for the current study had a brain MR scan 
for purposes of image co-registration and placement of VOIs for SPECT quantification. All VOIs were 
drawn bilaterally; however due to the lack of considerable differences between VOIs in left and right 
hemispheres, the results for the average VOI are reported. For each animal, a standard VOI template 
included the following brain regions: brainstem, midbrain, thalamus, caudate, putamen, frontal cortex, 
occipital cortex, cerebellum and subcortical white matter. 
Averaged images of SPECT data were generated by averaging the scans presenting the highest 
radioactivity from cortical and subcortical brain structures. The averaged image was used to co-register to 
a MR template from the same animal using an automatic rigid matching tool or when necessary manual 
alignment of both imaging modalities, by adjusting translation and rotation of the images. The 
transformation matrix was saved and consequently applied to all individual dynamic scans of the 
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corresponding co-registered SPECT study. Finally, the MR-derived VOIs templates were applied to the 
final co-registered SPECT images for generation of time-activity curves.  
 
Data analysis 
Time-activity curves were generated for each brain region and standard uptake values (SUV) 
were calculated according to equation 1. The target-non target ratio was expressed as SUVr, i.e. SUV 
value of target region divided by SUV of occipital cortex, defined as reference region. Percentage 
washout from the brain was determined using equation 2. 
Concentration VOI targetSUV=
Injected dose
Animal weight
       (Eq. 1) 
 
Initial conc. VOI target- Final conc. VOI target% Washout = ×100
Initial conc. VOI target
      (Eq. 2) 
where conc. = concentration. The initial and final concentrations were the radioactive concentrations at 
beginning and end of acquisition.  
For the displacement study using the bolus plus constant infusion protocol, specific binding in 
different brain regions was obtained by subtracting the mean occipital cortex uptake. Percent specific 
binding displacement was calculated using equation 3:  
SB prior displacement - SB post displacement% Displacement = ×100
SB prior displacement
  (Eq. 3) 
where SB is specific binding. 
GraphPad Prism 4.0 (GraphPad Software, USA) was used for curve fitting. 
 
Results: 
SPECT images demonstrating the distribution of 123I-NKJ64 and 123I-INER in baboon brain are 
shown in Fig. 2a and 2b, respectively. A homogeneous distribution of radioactivity was observed 
following intravenous bolus injection of 123I-NKJ64, such that the uptake in the brainstem and midbrain, 
the regions of baboon brain richest in NAT, was similar to that in other brain regions. Conversely, a 
markedly higher accumulation of radioactivity at the level of the brainstem and midbrain compared to the 
lower radioactivity accumulation in the cerebellum, caudate and occipital cortex was observed following 
intravenous bolus injection of 123I-INER (Fig. 2b).  
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Following intravenous bolus injection of 123I-NKJ64, whole brain uptake peaked at 20 minutes; 
the percentage of injected dose (%ID) in brain was 2.86%. At 240 minutes post-injection, 73% of whole 
brain initial uptake had been eliminated. The regional uptake of 123I-NKJ64 was as follows: thalamus, 
caudate and putamen > midbrain, brainstem and subcortical white matter > frontal cortex, cerebellum and 
occipital cortex (Fig. 3a). Following intravenous bolus injection of 123I-INER, whole brain uptake peaked 
at 20 minutes; the %ID in brain was 2.50%. 123I-INER had a slower washout from the brain compared 
with 123I-NKJ64, such that at 240 minutes post-injection 64% of whole brain uptake was eliminated. The 
regional uptake of 123I-INER was as follows: brainstem > midbrain > thalamus, caudate, putamen, 
cerebellum and white matter > frontal cortex > occipital cortex (Fig. 3b).  
Target:non target ratios determined following intravenous bolus injection of 123I-NKJ64, 
expressed as target SUV relative to occipital SUV, were high in the thalamus, caudate and putamen and 
low in the frontal cortex and cerebellum (Fig. 4a). Conversely, intravenous bolus injection of 123I-INER 
resulted in high target:non target ratios in brainstem and midbrain and a low ratio in frontal cortex (Fig. 
4b). Bolus injection of 2.0 mg/kg of reboxetine during bolus plus constant infusion experiments using 
123I-NKJ64 did not reduce the radioactive concentration in any of the evaluated brain regions, including 
NAT-rich regions such as brainstem and midbrain (Fig. 5). This contrasts with previous bolus plus 
constant infusion experiments with 123I-INER, which demonstrated that bolus injection of 1.0 mg/kg of 
reboxetine significantly reduced uptake in NAT rich regions (60% displacement) (Tamagnan et al., 2007).  
The results from blood sampling following intravenous bolus injection of 123I-NKJ64 or 123I-
INER are shown in Table I. At 60 minutes post-injection of 123I-NKJ64, the parent fraction in venous 
blood was 32%, and declined over time reaching a value of less than 14% at 240 minutes post injection. 
At 60 minutes post-injection of 123I-INER, the parent fraction in venous plasma was 31% and decline over 
time reaching a value of less than 13% at 240 minutes post-injection. Analysis of HPLC chromatograms 
from venous blood samples collected pre- and post- administration of reboxetine, during bolus plus 
constant infusion experiments using 123I-NKJ64 or 123I-INER, showed no differences in the metabolic 
profile of the parent compound for both radiotracers. 
 
Discussion: 
The pharmacokinetics and brain distribution of 123I-NKJ64 in non-human primates was 
investigated in this project and it was compared with its stereoisomer, 123I-INER. 123I-NKJ64 rapidly and 
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avidly entered the baboon brain, reaching a peak %ID in whole brain of 2.86%. The whole brain uptake 
of 123I-NKJ64 in baboon brain was similar to its stereoisomer, 123I-INER (%ID in brain = 2.50% at 20 
minutes post-injection). In comparison with other SPECT and PET radiotracers, whole brain uptake of 
123I-NKJ64 was either greater or similar (McConathy et al., 2004; Schou et al., 2003; Schou et al., 2007; 
Seneca et al., 2006).  
Despite the high whole brain uptake, the distribution of 123I-NKJ64 in baboon brain was 
inconsistent with known distribution of NAT in non-human primate brain (Smith et al., 2006). Analysis 
of 123I-NKJ64 SPECT images obtained in baboons showed that the highest uptake was in the caudate and 
putamen, regions that are known to have low NAT density (Smith et al., 2006). Binding ratios determined 
for 123I-NKJ64 where also highest in caudate and putamen. However, the uptake in the caudate and 
putamen was not due to specific binding to the NAT, since no displacement was observed in these regions 
following intravenous administration of the NAT blocking drug, reboxetine. The mechanism underlying 
the relatively high uptake in the caudate and putamen, remains unknown. However, some authors have 
suggested the existence of low-affinity NAT binding sites in the striatum as an explanation for the high 
striatal uptake frequently observed with NAT radiotracers (Ding et al., 2003).  In vivo administration of a 
high dose of the reboxetine resulted in no displacement of 123I-NKJ64 uptake in any of the other evaluated 
brain regions including the brainstem or midbrain. This suggests that the in vivo uptake of 123I-NKJ64 in 
baboons is not due to specific binding of the radiotracer to the NAT and that 123I-NKJ64 has a low affinity 
for the NAT in vivo in baboon brain. In contrast, 123I-INER, a stereoisomer of 123I-NKJ64, showed a 
distribution pattern in baboon brain consistent with known NAT densities in non-human primate brain. 
Moreover, 60% of 123I-INER binding was displaced following intravenous injection of a lower dose of 
reboxetine than we used in the present study (Tamagnan et al., 2007). The lower in vitro affinity of 123I-
NKJ64 in comparison with 123I-INER (KD in rat frontal cortex of 4.8 nM and 1.3 nM, respectively) 
(Kanegawa et al., 2006; Tavares et al., 2011a) may explain the differences in distribution and kinetics 
between 123I-NKJ64 and 123I-INER in vivo. Although high in vitro affinity does not guarantee the success 
of a radiotracer in vivo, it is desirable, particularly when imaging low density molecular targets, such as 
the NAT.  In 2009, Zeng et al. observed differences in the brain distribution and kinetics among different 
reboxetine analogues labelled with 11C or 18F with a range of affinities for the NAT. These authors 
suggested that radiotracers with low affinity for NAT will not enable the visualisation of a specific 
binding signal in NAT-rich regions using PET due to a low signal-to-noise ratio (Zeng et al., 2009). 
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Another contributory factor to the observed differences between 123I-INER and 123I-NKJ64 could be their 
relative selectivity for NAT over the transporters for serotonin (SERT) and dopamine (DAT). The 
calculated ratios of affinity for NAT relative to the other amine transporters were: SERT/NAT=51 and 
DAT/NAT=270 for 123I-INER versus SERT/NAT=6 and DAT/NAT=63 for 123I-NKJ64 (Jobson et al., 
2009; Tamagnan et al., 2007). The binding of 123I-NKJ64 to other aminergic transporters could contribute 
to the 123I-NKJ64 uptake measured in non-target regions in vivo in non-human primate brain in 
comparison to 123I-INER.  
There have been previous reports of differences in the biodistribution and kinetics in vivo of 
stereoisomers of compounds other than 123I-NKJ64 and 123I-INER.   For example, a study evaluating the 
distribution and kinetics of 11C-labelled (S,S)- and (R,R)-MRB, two reboxetine stereoisomers, showed that 
only (S,S)-11C-MRB presented the favourable characteristics for imaging of NAT in vivo. However, 
(R,R)-11C-MRB did not exhibit regional specificity and was not blocked by administration of nisoxetine 
suggesting enantioselectivity of MRB in vivo (Ding et al., 2003).  123I-NKJ64 is the first (R,S)-reboxetine 
analogue to be synthesised and investigated in vivo as an imaging agent.  This study demonstrated 123I-
NKJ64 to be unsuccessful as a radiotracer for the visualisation of the NAT in vivo in baboons, and 
therefore any future development of radiotracers based on reboxetine may be best focussed on the (S,S)-
stereoisomers that have higher affinity for the NAT.  
The results presented here illustrate the effect that species differences can have on radiotracer 
performance in vivo. In contrast to the present study in baboons, our previous study in rats demonstrated 
that the brain distribution of 123I-NKJ64 was consistent with known NAT density and moreover that 123I-
NKJ64 had a good target non-target ratio in rat brain (Tavares et al., 2011a). The differences between the 
way 123I-NKJ64 behaves in rats and baboon could be due to numerous factors. These include the known 
differences in NAT density in rat and non-human primate brain. In non-human primate brain, the locus 
coeruleus has a NAT binding site density of around 220 fmol/mg, while the rodent locus coeruleus has a 
density of around 1500 fmol/mg (Smith et al., 2006; Tejani-Butt, 1992). Thus, rat brain has seven times 
more NAT binding sites than non-human primate brain. It is worth noting that that the density of NATs in 
human cerebral cortex is approximately nine times lower than in rodents (Schou et al., 2006). 
Consequently, the present results obtained with 123I-NKJ64 in baboons, and the known differences in 
NAT densities across species, preclude the translation of 123I-NKJ64 for use in humans.  
11 
 
It is unlikely that the quantification of 123I-NKJ64 and 123I-INER kinetics and distribution in 
baboon brain reported here was affected by radiolabelled metabolites generated in blood. Only a single 
metabolite was present in venous plasma and this was less lipophilic than the parent radiotracers. Since 
the metabolite is less lipophilic than the parent radiotracers it is unlikely to pass the blood-brain barrier 
and contribute to brain radioactivity. In addition, the time-activity curves obtained for all brain regions, 
after intravenous bolus injection of the radiotracer, had a single initial peak followed by continuous 
elimination over the duration of the study, supporting the hypothesis that there were no metabolites 
present in the brain over time. Both these observations provide support for the interpretation that the 
uptake in baboon brain was not due to metabolites generated either in tissue or in blood. The metabolic 
pattern of 123I-NKJ64 in venous blood was similar to that of 123I-INER. This suggests that differences in 
brain distribution and radiotracer pharmacokinetics in vivo between 123I-NKJ64 and 123I-INER were not 
due to differences in metabolism. Analysis of blood collected during displacement experiment showed no 
difference in the parent compound fraction in plasma taken post administration of reboxetine compared to 
plasma taken pre-administration of reboxetine. This suggests that there was no displacement of 123I-
NKJ64 binding in non-target organs indicating that there is no specific binding of 123I-NKJ64 to 
peripheral organs. A similar observation was made in rats such that administration of reboxetine did not 
reduce 123I-NKJ64 binding in any of the investigated peripheral organs (Tavares et al., 2011a). 
In conclusion, the present data suggest that 123I-NKJ64, may lack affinity and selectivity for 
NAT in baboon brain, and the high levels of non-specific binding could be obscuring any 123I-NKJ64 
specific binding that might be present in vivo. Despite promising preliminary evaluation in rodents, the 
data obtained from non-human primates do not support further studies with 123I-NKJ64 and its translation 
for use in human imaging studies. Thus, to date, the most promising SPECT radiotracer developed for in 
vivo imaging of NAT in brain is 123I-INER.  
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Table I. Results from metabolite analysis in venous blood following intravenous injection of 123I-NKJ64 
and 123I-INER. Note the similar metabolic parent fraction in venous blood at selected time points 
following intravenous bolus injection of either radiotracer. 
Metabolite analysis 30 min. p.i. 60 min. p.i. 240 min. p.i. 
123I-NKJ64 123I-INER 123I-NKJ64 123I-INER 123I-NKJ64 123I-INER 
Metabolite A 49.8 46.6 67.9 69.3 86.5 87.2 
Parent 50.3 53.4 32.1 30.7 13.6 12.8 
1p.i. = post-injection 
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Figure Legends 
 
Fig. 1 Chemical structures of reboxetine and its analogues developed for PET and SPECT imaging of the 
NAT in brain. 
 
Fig. 2 Brain SPECT images showing the distribution of 123I-NKJ64 (a) and 123I-INER (b) in baboons. 
Transverse, sagittal and coronal planes (left to right). The greatest accumulation of radioactivity is shown 
in red and the least in green. Note differences in brain distribution between SPECT images acquired using 
123I-NKJ64 compared with 123I-INER. Uptake of 123I-NKJ64 in brainstem (red arrows) is not different 
from other brain structures (a) while uptake of 123I-INER in brainstem is greater than other brain regions 
(b). 
 
Fig. 3 Time-activity curves derived from SPECT data acquired following intravenous bolus injection of 
123I-NKJ64 (a) and 123I-INER (b). Note the higher uptake in brainstem and midbrain compared to other 
brain regions after injection of 123I-INER, at later time points which is not seen after injection of 123I-
NKJ64. 
 
Fig. 4 Binding ratios of 123I-NKJ64 (a) and 123I-INER (b) in different brain regions following bolus 
intravenous injection of the radiotracer. For 123I-NKJ64 (a) binding ratios in NAT-rich regions, i.e. the 
brainstem and the midbrain, were similar to those of other regions but for 123I-INER (b) binding ratios in 
NAT-rich regions were greater than other regions. 
 
Fig. 5 Uptake of 123I-NKJ64 in baboon brain pre- and post-administration of reboxetine. Time-activity 
curve obtained following bolus plus constant infusion of 123I-NKJ64. The reboxetine bolus was 
administered  2.75 hours after radiotracer injection (indicated by black line and arrow).  Note the absence 
of change in radioactive concentration post-administration of reboxetine in any of the evaluated brain 
regions. 
 
